As the weather in the Washington D.C., area starts ebbing from shorts and T-shirts to jeans and hoodies, Autumn signals its arrival and therefore, the focus of Endocrine News turns to our annual diabetes research and practice issue each November, to coincide with Diabetes Awareness Month. As usual, thanks to the plethora of research on...
Fresh from receiving a 2022 Endocrine Society Early Investigator Award, Estelle Everett, MD, MHS, was a member of this year’s Dimensions in Diabetes program that took place in Mumbai, India, in August. She talks to Endocrine News about that program, her own research, and how the award has impacted her career. In August 2023,...
Hypoglycemia from overtreatment is a serious but seldom recognized complication in older adults with type 2 diabetes. A new decision support tool developed by the Endocrine Society can help primary care providers avoid overtreatment and cut the risk of hypoglycemic events in these patients. The use of a clinical decision support tool can reduce the risk...
More than 100 years after the discovery of insulin galvanized our field, diabetes research and care remain a central part of endocrinology. Diabetes Awareness Month offers the opportunity to reflect on the importance of our research and clinical care to millions of people around the globe. For the 540 million people worldwide living with diabetes,...
For decades, physicians have maintained that type 2 diabetes could be delayed or even prevented altogether simply by modifying certain behaviors. Priyanka Majety, MD, talks to Endocrine News about pharmacological options that could help these patients, but lifestyle modifications are still crucial. As we enter National Diabetes Month and head toward World Diabetes Day on...
Cutting-edge advancements in endocrinology continue to move diabetes treatment in the right direction faster than ever before. The treatment of diabetes is continually evolving. More than a century ago, a diabetes diagnosis was a death sentence, and although there is not yet a cure, endless updates in diabetes care help ease the burden of both...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Approves Lilly’s Zepbound™ (tirzepatide) for Chronic Weight Management On November 8, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company’s (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide)...
On November 8, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company’s (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Zepbound is indicated for adults with obesity (with a BMI of 30 kg/m2 or greater), or those who...